Pulse Biosciences Inc (PLSE) - Total Assets
Based on the latest financial reports, Pulse Biosciences Inc (PLSE) holds total assets worth $81.62 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Pulse Biosciences Inc balance sheet independence to measure how much of total assets are equity-financed.
Pulse Biosciences Inc - Total Assets Trend (2014–2025)
This chart illustrates how Pulse Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Check PLSE tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Pulse Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Pulse Biosciences Inc's total assets of $81.62 Million consist of 86.8% current assets and 13.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.0% |
| Accounts Receivable | $274.00K | 0.3% |
| Inventory | $136.00K | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $575.00K | 0.6% |
| Goodwill | $2.79 Million | 2.9% |
Asset Composition Trend (2014–2025)
This chart illustrates how Pulse Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Pulse Biosciences Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pulse Biosciences Inc's current assets represent 86.8% of total assets in 2025, an increase from 39.3% in 2014.
- Cash Position: Cash and equivalents constituted 84.0% of total assets in 2025, up from 39.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 59.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 2.9% of total assets.
Pulse Biosciences Inc Competitors by Total Assets
Key competitors of Pulse Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
AVE Science & Technology Co Ltd
SHG:688067
|
China | CN¥611.46 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
Pulse Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.26 | 15.58 | 6.27 |
| Quick Ratio | 7.24 | 15.58 | 6.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $61.33 Million | $113.15 Million | $51.91 Million |
Pulse Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Pulse Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.65 |
| Latest Market Cap to Assets Ratio | 13.54 |
| Asset Growth Rate (YoY) | -27.4% |
| Total Assets | $96.11 Million |
| Market Capitalization | $1.30 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Pulse Biosciences Inc's assets at a significant premium (13.54x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Pulse Biosciences Inc's assets decreased by 27.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pulse Biosciences Inc (2014–2025)
The table below shows the annual total assets of Pulse Biosciences Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $96.11 Million | -27.44% |
| 2024-12-31 | $132.46 Million | +123.92% |
| 2023-12-31 | $59.15 Million | -24.04% |
| 2022-12-31 | $77.88 Million | +43.55% |
| 2021-12-31 | $54.25 Million | +31.38% |
| 2020-12-31 | $41.29 Million | -1.48% |
| 2019-12-31 | $41.91 Million | -40.66% |
| 2018-12-31 | $70.64 Million | +41.79% |
| 2017-12-31 | $49.82 Million | +89.33% |
| 2016-12-31 | $26.31 Million | +83.69% |
| 2015-12-31 | $14.33 Million | -19.95% |
| 2014-12-31 | $17.90 Million | -- |
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac… Read more